The 2025 American Academy of Dermatology (AAD) Annual Meeting

Orlando, Florida, US 07 March 2025 - 11 March 2025

Two-ingredient diaper wipes gentle on skin affected by eczema

05 Apr 2025 by

Wipes formulated with purified water plus fruit extract for sensitive skin are safe to use on babies with eczema-prone skin or active eczema, according to a study.

Two-ingredient diaper wipes gentle on skin affected by eczema

05 Apr 2025

Is vitiligo as side effect a good sign for cancer patients on immunotherapy?

03 Apr 2025 by

Vitiligo occurs as a cutaneous immune-related adverse event during immune checkpoint inhibitor (ICI) therapy in most melanoma and nonmelanoma cancer patients with partial or complete response to treatment, according to a systematic review.

Is vitiligo as side effect a good sign for cancer patients on immunotherapy?

03 Apr 2025

Lebrikizumab relieves itch, skin pain in AD patients previously on dupilumab

28 Mar 2025 by

The use of lebrikizumab improves the symptoms of moderate-to-severe atopic dermatitis (AD) in patients previously treated with dupilumab, reports a study presented at AAD 2025.

Lebrikizumab relieves itch, skin pain in AD patients previously on dupilumab

28 Mar 2025

Remibrutinib improves sleep, daily activities in patients with CSU

28 Mar 2025 by

Treatment with remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, improved sleep and daily activities in patients with chronic spontaneous urticaria (CSU), according to two phase III REMIX-1 and -2 studies presented at AAD 2025.

Remibrutinib improves sleep, daily activities in patients with CSU

28 Mar 2025

Apremilast boasts long-term improvement in PPP

27 Mar 2025 by

Patients with palmoplantar pustulosis (PPP) treated with apremilast show improvements at week 16, with continued treatment resulting in maintained or further improvement at week 52, according to a study presented at AAD 2025. No new safety concerns have been observed.

Apremilast boasts long-term improvement in PPP

27 Mar 2025

Baricitinib tied to hair regrowth in adolescents with severe AA

26 Mar 2025 by

Once-daily treatment with baricitinib resulted in clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes among adolescent patients with severe alopecia areata (AA), according to the BRAVE-AA-PEDS trial presented at AAD 2025.

Baricitinib tied to hair regrowth in adolescents with severe AA

26 Mar 2025

Eyebrow or eyelash hair loss affects QoL in AA patients

25 Mar 2025 by

A real-world analysis presented at AAD 2025 shows that patients with alopecia areata (AA) with eyebrow or eyelash hair loss have greater health-related quality of life (HRQoL) burden than those without eyebrow and eyelash involvement.

Eyebrow or eyelash hair loss affects QoL in AA patients

25 Mar 2025

Composite metric boosts tapinarof efficacy for AD

20 Mar 2025 by

Two pivotal phase III trials show that a once-daily application of tapinarof cream 1% yields rapid treatment response – as indicated by the vIGA-AD™×BSA* composite score – in individuals with moderate-to-severe atopic dermatitis (AD).

Composite metric boosts tapinarof efficacy for AD

20 Mar 2025